Orano USA’s Post

VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently serves as the general manager and chief strategy officer for Pharmalogic, a leading contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers. He has served on Nusano’s board since September 2022. Holbrook brings over 25 years of experience growing companies in biotech and radiopharmaceuticals to the role. His experience will be critical as Nusano begins commercialization and scale-up of its proprietary medical radioisotope production technologies. “Many highly promising cancer treatments in development are in desperate need of a reliable supply of medical radioisotopes,” said Holbrook. “Nusano’s proprietary technologies are poised to make many of these critical components available and abundant in ways no other production method can. It’s an honor to have this opportunity to lead the board and help advance an exciting new era in radiotherapeutics.” Chris Lowe, CEO of Nusano, commented, “Scott has been an invaluable member of our board and is a passionate advocate for patients. As our production capacity comes online, his strategic insights and experience will help ensure our customer needs are met in a timely and reliable manner.” Radioisotopes are essential components in the active pharmaceutical ingredients (API) of a category of new and emerging cancer therapies, known as radiotherapeutics. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development. Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to commercial markets. The company expects to begin producing and delivering commercial-scale quantities of lutetium-177 in Q1 2025 and actinium-225 in the second half of 2025. Nusano’s first-of-its-kind production facility opens Q1 2025 in West Valley City, Utah. At full scale it will be capable of producing more than 25 radioisotopes of interest to medicine, and the simultaneous production of up to 12 different radioisotopes. In addition to his roles at Nusano and PharmaLogic, Holbrook serves as an adjunct professor in the Department of Radiology at the University of Utah, and on the board of Ratio Therapeutics. He holds a Master of Science in Molecular Imaging and Therapy from Regis College and a Bachelor of Science in Clinical Nuclear Medicine from Wheeling University. #radiopharmaceuticals #radiotherapy #radioisotopes #lutetium #lutetium177 #actinium #actinium225 #fightingcancer

Radionuclide therapy, #radiotheranostics, #radioligand therapy, targeted alpha therapy, etc. Easy to get lost, right? 😅 Take a look to our 1° #BFPLab glossary! 📚 Share with us your definitions or send us the terms you want to find in our 2° edition 🔎 P.S. All sources are cited below. #radiopharmaceuticals #nuclearmedicine #radiofarmaci #medicinanucleare

2023 was both a productive and fun year for #Lantheus! Our CEO Mary Anne Heino recently reflected on #TeamLantheus’ accomplishments in 2023, shining a spotlight on our commitment to patients and to innovation as the leading radiopharmaceutical-focused company. We can’t wait to see what 2024 holds! Watch the video below to hear Mary Anne share highlights over the last year ⬇️   #radiopharmaceuticals #OneLantheus #FindFightFollow

More exciting news for Humacyte!!

Join us on 16 July at 15:00 CEST for an enlightening webinar on "Advancements in inhalable nano-drug delivery systems for targeted lung therapy” organised by FIP’s Industrial Pharmacy Section. Discover the advantages of pulmonary drug delivery, learn about the challenges in delivering inhalable therapies to the lungs, and gain insights into designing drug-loaded nanoparticles for effective pulmonary applications. Don't miss this opportunity to deepen your knowledge in this cutting-edge field! https://lnkd.in/dRvPhWc6

In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together. #nucmed #radonc https://lnkd.in/em4UYN5V

🚀 Exciting News from Auxilius Pharma! 🚀 We're thrilled to announce that Auxilius Pharma is set to revolutionize the treatment of chronic stable angina pectoris (CSAP) with their latest innovation, AUX-001! 🌟 AUX-001 is a groundbreaking, once-daily version of nicorandil, developed to enhance patient convenience and adherence. With a successful Phase Ia trial already under our belt, they are gearing up to submit an IND application and kick off a Phase Ib trial in Q4 2024 or early Q1 2025. 📅 Their Phase Ib study aims to demonstrate the bioequivalence of AUX-001, setting the stage for a pivotal Phase III trial in H2 2025. This could be a game-changer in the management of CSAP, offering a simpler, more effective treatment option for patients. 💡 Stay tuned for more updates on our journey to transform cardiovascular care! 💖 #Auxilius #AUX001 #ChronicStableAngina #CSAP #CardiovascularHealth #PhaseIbTrial #ClinicalTrials #FDA #INDApplication #PharmaceuticalInnovation #Nicorandil #Bioequivalence #PhaseIII #PatientCare #HealthcareInnovation #DrugDevelopment #PharmaIndustry #MedicalResearch #Cardiology #HeartHealth #AnginaTreatment #PharmaNews #LifeSciences #Biotech #HealthTech #ClinicalResearch #biotech #innovation #news

GPCR Therapeutics is thrilled to announce a significant out-licensing agreement with Bridge Biotherapeutics, Inc. focused on the development and commercialization of a combination therapy involving our CXCR4-LPA1 inhibitor method, to aid our pursuit of innovative treatments for Idiopathic Pulmonary #Fibrosis (IPF). The scientific basis for this approach was recently published in the peer-reviewed journal 'Cell Communication and Signalling,' (https://lnkd.in/exTvdTxP) highlighting the potential of this innovative treatment for fibrotic diseases like IPF. We are excited about the prospects this collaboration brings and the opportunity to explore new avenues in IPF treatment alongside Bridge Biotherapeutics. IPF is a chronic lung condition causing scarring, making breathing progressively difficult. With no current treatment to halt or reverse scarring, our joint efforts aim to revolutionize IPF treatment and improve outcomes for patients. 📝 Read our press release: http://gpcr.co.kr/news/ 🔗 Learn more about our platform technology: https://lnkd.in/eH8YveC8 #BioTech #LungDisease #LungHealth

https://lnkd.in/eXJSG6sy We’re thrilled to announce that our investigational Acellular Tissue Engineered Vessel (ATEV™) has received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for advanced Peripheral Artery Disease (PAD) treatment. This marks our third RMAT designation, a testament to our commitment to innovation and patient care. Our previous RMAT designations were for vascular trauma repair and arteriovenous (AV) access in hemodialysis. What does this mean?  The RMAT designation has the potential to accelerate the development and review process, allowing us to work closely with the FDA and potentially an expedited/priority review of a Biologics License Application (BLA). Our ATEV is designed to be a universally implantable vascular conduit, offering a potential option for PAD patients who lack other treatment options.  Stay tuned as we continue to advance this exciting technology, with the goal of improving outcomes for PAD patients worldwide. #Humacyte #Innovation #Healthcare #Biotech #FDA #RMAT #PAD #VascularHealth

We are thrilled to announce that JEITO has led a €75M Series B financing round for NMD Pharma A/S, a Danish clinical-stage biotech company dedicated to developing innovative treatments for patients living with severe neuromuscular disorders. Following our initial investment in 2022, this second round of funding illustrates our steady support to growing and perfoming NMD Pharma A/S and its ambition to become a leading, global, clinical-stage company. The proceeds will be used to complete three Phase 2 clinical Proof of Concept studies with NMD670, the company's leading CIC-1 inhibitor, which has the potential to restore muscle function in a range of rare neuromuscular diseases, including myasthenia gravis, spinal muscular atrophy, and Charcot Marie Tooth. The funding will also contribute to grow its pipeline and support the expansion of NMD Pharma’s clinical and commercial operations in Denmark and in the US. We are very proud to stand alongside Thomas Holm Pedersen, the CEO, and his team as they embark on this new chapter, driven by their unwavering commitment to making a positive impact on patients. Read more 👉 https://lnkd.in/ev_3hjv8 #FasterForThePatient #privateequity #lifesciences #biopharma #healthcare #neuromusculardisease